CL2024002070A1 - Derivados del azaindol y su uso como inhibidores de la erk–quinasa - Google Patents

Derivados del azaindol y su uso como inhibidores de la erk–quinasa

Info

Publication number
CL2024002070A1
CL2024002070A1 CL2024002070A CL2024002070A CL2024002070A1 CL 2024002070 A1 CL2024002070 A1 CL 2024002070A1 CL 2024002070 A CL2024002070 A CL 2024002070A CL 2024002070 A CL2024002070 A CL 2024002070A CL 2024002070 A1 CL2024002070 A1 CL 2024002070A1
Authority
CL
Chile
Prior art keywords
erk
kinase inhibitors
azaindole derivatives
azaindole
derivatives
Prior art date
Application number
CL2024002070A
Other languages
English (en)
Spanish (es)
Inventor
Bories Cédric
Mathieu Loïc
Guichou Jean-François
Gelin Muriel
Biechy Aurélien
Original Assignee
Agv Discovery
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agv Discovery, Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Montpellier filed Critical Agv Discovery
Publication of CL2024002070A1 publication Critical patent/CL2024002070A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2024002070A 2022-01-14 2024-07-09 Derivados del azaindol y su uso como inhibidores de la erk–quinasa CL2024002070A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22305031.1A EP4212531A1 (en) 2022-01-14 2022-01-14 Azaindole derivatives and their use as erk kinase inhibitors

Publications (1)

Publication Number Publication Date
CL2024002070A1 true CL2024002070A1 (es) 2024-11-29

Family

ID=80445694

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002070A CL2024002070A1 (es) 2022-01-14 2024-07-09 Derivados del azaindol y su uso como inhibidores de la erk–quinasa

Country Status (16)

Country Link
US (3) US11827637B2 (cg-RX-API-DMAC7.html)
EP (2) EP4212531A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025502377A (cg-RX-API-DMAC7.html)
KR (1) KR20240134887A (cg-RX-API-DMAC7.html)
CN (1) CN118541370A (cg-RX-API-DMAC7.html)
AR (1) AR128267A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023207276A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002070A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024008809A2 (cg-RX-API-DMAC7.html)
IL (1) IL314199A (cg-RX-API-DMAC7.html)
JO (1) JOP20240157A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024008629A (cg-RX-API-DMAC7.html)
TW (1) TW202334147A (cg-RX-API-DMAC7.html)
UA (1) UA130477C2 (cg-RX-API-DMAC7.html)
WO (1) WO2023135233A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2025012357A1 (en) * 2023-07-12 2025-01-16 Ipsen Pharma Fluorinated azaindole derivatives and their use as erk kinase inhibitors
WO2025012386A1 (en) * 2023-07-12 2025-01-16 Agv Discovery Crystalline form of (s)-1-(1-(3-chlorophenyl)-2- (dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3- b]pyridin-3-yl)pyridin-2(1h)-one, its preparation and its use as erk kinase inhibitor
AU2024297019A1 (en) * 2023-07-12 2026-01-22 Agv Discovery Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5- morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one, their preparation and their use as erk kinase inhibitors
EP4588918A1 (en) 2024-01-18 2025-07-23 AGV Discovery Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one
WO2026064271A1 (en) 2024-09-23 2026-03-26 Fmc Corporation Substituted bicyclic amide derivatives as herbicides
WO2026153964A1 (en) * 2025-01-15 2026-07-23 Ipsen Pharma Salts of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one for use in the treatment of melanoma with braf v600 mutation
WO2026153950A1 (en) 2025-01-15 2026-07-23 Ipsen Pharma Pharmaceutical compositions comprising (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)-4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one hydrochloride and at least one carboxylic acid

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CN100396678C (zh) 2004-11-16 2008-06-25 财团法人工业技术研究院 1-苯甲基-3-(5’-羟甲基-2’-呋喃基)吲唑的吲哚类似物的合成及用途
ES2431466T3 (es) 2006-06-30 2013-11-26 Sunesis Pharmaceuticals, Inc. Inhibidores de piridinonil pdk1
BRPI0713187A2 (pt) 2006-07-20 2012-10-16 Mehmet Kahraman método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
US8697697B2 (en) 2011-01-04 2014-04-15 Kinentia Biosciences Llc Pyrazole derivatives as ERK inhibitors
EP2739143B1 (en) 2011-08-05 2018-07-11 Gary A. Flynn Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
EP2909206A1 (en) 2012-10-16 2015-08-26 F. Hoffmann-La Roche AG Serine/threonine kinase inhibitors
GB2515785A (en) 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
CN113423707A (zh) * 2018-11-16 2021-09-21 加利福尼亚技术学院 Erk抑制剂及其用途
EP4212531A1 (en) * 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors

Also Published As

Publication number Publication date
TW202334147A (zh) 2023-09-01
JP2025502377A (ja) 2025-01-24
WO2023135233A1 (en) 2023-07-20
US11827637B2 (en) 2023-11-28
AR128267A1 (es) 2024-04-10
EP4212531A1 (en) 2023-07-19
CN118541370A (zh) 2024-08-23
JOP20240157A1 (ar) 2024-07-14
IL314199A (en) 2024-09-01
CA3242894A1 (en) 2025-02-28
MX2024008629A (es) 2024-08-19
US20230227451A1 (en) 2023-07-20
US12421231B2 (en) 2025-09-23
CO2024008809A2 (es) 2024-08-08
AU2023207276A1 (en) 2024-08-01
US20240308997A1 (en) 2024-09-19
EP4463453A1 (en) 2024-11-20
UA130477C2 (uk) 2026-02-25
KR20240134887A (ko) 2024-09-10
US20260042758A1 (en) 2026-02-12

Similar Documents

Publication Publication Date Title
CO2024008809A2 (es) Derivados del azaindol y su uso como inhibidores de la erk–quinasa
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
GEAP202416075A (en) New macrocyclic lrrk2 kinase inhibitors
CL2022000447A1 (es) Inhibidores de kras g12d
MX391410B (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
DOP2019000184A (es) Inhibidores selectivos de jak1
UY36152A (es) Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
BR112021022536A2 (pt) Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo
CL2022001951A1 (es) Compuestos heterocíclicos novedosos útiles como inhibidores selectivos de aurora a
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
MX382166B (es) Compuestos de indazol como inhibidores de cinasa fgfr, preparacion y uso de los mismos.
CR11433A (es) Inhibidores de quinasa c-fms
BR112015022993A8 (pt) inibidores de jak2 e alk2 e métodos para sua utilização.
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
DOP2021000066A (es) Compuestos, composiciones, y métodos para modular la actividad cdk9
BR112022002222A2 (pt) Derivados de quinolina como inibidores de proteínas quinases
EA201400831A1 (ru) Пиразолопиримидиниловые ингибиторы убиквитин-активирующего фермента
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CL2025002505A1 (es) Compuestos derivados de pirazolopirimidina inhibidores del inflamasoma nlrp3.
MX2021010131A (es) Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
CR20210661A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos